Every 10-Q that Skye Bioscience (SKYE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SKYE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKYE filings page.
Skye Bioscience, Inc. reported a sharp contraction in its balance sheet as it winds down its legacy obesity program and pursues a merger with Redx Pharma. Total assets fell to $11.0 million at June 30, 2026 from $28.3 million at year-end 2025, driven by lower short-term investments and asset impairments. The company recorded a six-month net loss of $23.3 million, narrower than the prior year, as research and development expenses declined 45% after terminating the CBeyond nimacimab trial and pausing related R&D.
Liquidity remains strained with a working capital deficit of $572,215, cash and short-term investments of $10.1 million, and a disclosed substantial doubt about its ability to continue as a going concern absent completion of the Redx transaction or new financing. Skye increased its estimate for a legal contingency to $5.4 million related to a former-employee proceeding. To address capital needs, Skye agreed to acquire Redx via a Scheme of Arrangement, supported by a $67.9–$72.9 million concurrent equity financing, a separate $36.0 million Redx Series A round, an equity line of credit of up to $22.0 million, and a $5.0 million warrant. The board also approved a planned 1-for-8 reverse stock split as it works to maintain Nasdaq listing compliance.
Skye Bioscience (SKYE) filed its Q3 2025 10‑Q, reporting wider losses as it advances obesity drug development. The company posted a net loss of $12,754,660 for the quarter. Operating expenses rose to $13,264,534, driven by research and development of $9,357,444 and general and administrative costs of $3,907,090.
Liquidity remained solid for near‑term plans: cash and cash equivalents were $18,441,079 and short‑term investments were $16,871,229, totaling $35,312,308 as of September 30, 2025. Total stockholders’ equity was $32,836,185. As of November 7, 2025, 32,057,461 shares were outstanding.
In its CBeyond Phase 2a study, nimacimab monotherapy did not meet the primary endpoint for weight loss versus placebo. However, the combination of nimacimab 200 mg with semaglutide showed greater weight loss than semaglutide alone at 26 weeks and maintained a favorable safety profile. The 26‑week extension enrolled 43 patients, with data expected in Q1 2026.